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Most women with self-reported heavy menstrual bleeding will have a rapid 
decrease in flow following levonorgestrel 52mg intrauterine system 
placement.
SHORT TITLE
LNG 52mg IUS treatment of HMB
AJOG AT A GLANCE
Why was the study conducted?
 To evaluate cycle-by-cycle decrease in self-reported heavy menstrual 
bleeding (HMB) among women initiating levonorgestrel 52mg 
intrauterine system (IUS) use.
What are the key findings?
 HMB decreases significantly even with the first period after insertion, 
more than 90% of women no longer have subjective heavy bleeding 
within 6 months, and amenorrhea rates during the first year are lower 
than in women without self-reported baseline HMB.
What does this study add to what is already known?
 This study provides a cycle-by-cycle evaluation of bleeding changes, 
showing how rapidly flow decreases after LNG 52mg IUS insertion in 



























Background: The levonorgestrel 52mg intrauterine system (IUS) has proven
efficacy for heavy menstrual bleeding (HMB) treatment in clinical trials, but 
little data exists to demonstrate how rapidly the effects occur and the effects
in women with self-reported heavy bleeding as seen commonly in clinical 
practice.
Objective: Evaluate changes in bleeding patterns in women with self-
reported HMB prior to levonorgestrel 52mg IUS insertion.
Study Design: A total of 1,714 women aged 16-45 years old received a 
levonorgestrel 52mg IUS in a multicenter trial evaluating contraceptive 
efficacy and safety for up to 10 years. At screening, participants described 
their baseline menstrual bleeding patterns for the prior 3 months. 
Participants completed daily diaries with subjective evaluation of bleeding 
information for the first 2 years. For this analysis, we included women with at
least one complete 28-day cycle of IUS use and excluded women using a 
hormonal or copper intrauterine contraception in the month prior to study 
enrollment. We evaluated changes in menstrual bleeding and discontinuation
for bleeding complaints per 28-day cycle over 26 cycles (2 years) in women 
who self-reported their baseline pattern as heavy. We also compared rates of
amenorrhea, defined as no bleeding or spotting, within the entire study 
population in women with subjective HMB at baseline compared to those who

























Results: Of the 1513 women in this analysis, 150 (9.9%) reported baseline 
HMB. The majority of women reported no longer experiencing HMB by the 
end of cycle 1 (112/150, 74.7%) with even higher rates by cycle 2, (124/148, 
83.8%). At the end of cycles 6, 13 and 26, 129/140 (92.1%, 95% CI 87.7-
96.6%), 114/123 (92.7%, 95% CI 88.1-97.3%) and 100/103 (97.1%, 95% CI 
93.8-100%) women reported no HMB, respectively. After cycles 13 and 26, 
63/123 (51.2%, 95% CI 42.4-60.1%) and 66/103 (64.1%, 95% CI 54.8-73.3%),
respectively, reported their bleeding as amenorrhea or spotting only. A lower
proportion of women with baseline self-reported HMB reported amenorrhea 
as compared to women in the overall study cohort without HMB at the end of
6 cycles (319 [25.5%] vs. 21 [15.0%], p=.005) and 13 cycles (382 [34.4%] 
vs. 26 [21.1%], p=.003); differences were not significant after 19 cycles (367
[37.2%] vs. 36 [31.0%], p=.022) and 26 cycles (383 [43.5%] vs. 38 [36.9%], 
p=.21). Only 4 (2.7%) women with baseline HMB discontinued for bleeding 
complaints (2 for HMB and 2 for irregular bleeding), all within the first year.
Conclusions: Most women who self-report HMB experience significant 
improvement quickly after levonorgestrel 52mg IUS insertion. 
Discontinuation for bleeding complaints among women with baseline HMB is 
very low.
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Normal menstrual blood loss (MBL) ranges between 20 and 60 
mL/cycle. Heavy menstrual bleeding (HMB), formerly referred to as 
menorrhagia, is excessive blood loss that occurs alone or in combination with
other symptoms and has a negative impact on a woman’s physical, social, 
emotional, and material quality of life (1). Although studies for agency 
approval typically define HMB as MBL ≥80 mL per cycle, only about half of 
women who complain of HMB meet these criteria (1,2). 
Approximately 30% of women are affected by HMB during their 
reproductive years, resulting in increased health costs (3). A variety of 
functional, structural, and non-structural conditions can cause HMB, including
adenomyosis, leiomyomas, and coagulopathies as well as iatrogenic causes. 
In many women, the underlying cause of HMB is unknown and is referred to 
as functional HMB (4). 
In the early 1990s, the levonorgestrel 52mg intrauterine system (IUS) 
emerged as an option for medical management of HMB. While oral 
progestins have variable effects, combined oral contraceptives, non-steroidal
anti-inflammatory drugs and antifibrinolytics can reduce MBL by 40-50% 
within a few cycles of treatment, a levonorgestrel 52mg IUS can decrease 
measured MBL by 71% within 6 months and up to 94% after 1 year (5,6). 
Additionally, the levonorgestrel 52mg IUS provides greater improvement in 

























psychological and physical well-being compared to usual medical treatment 
(1,7-9).
Although data from clinical trials evaluate outcomes in women with a 
quantifiable level of blood loss per cycle, clinical guidelines recognize that 
the diagnosis should be based on subjective measures rather than the 
objective measure of MBL because HMB has a major impact on a woman’s 
quality of life, (10). No prospective study has reported the impact of a 
levonorgestrel 52mg IUS in U.S. women with “real-life” HMB. This report 
describes bleeding changes and outcomes over the first two years of 
levonorgestrel 52mg IUS use among participants in a Phase 3 contraceptive 
trial who self-reported baseline HMB.
Materials and Methods
This secondary analysis includes data from the ACCESS IUS (A 
Comprehensive Contraceptive Efficacy and Safety Study of an IUS) 
multicenter, open-label trial of Liletta® (Medicines360, San Francisco, CA and
Allergan, Irvine, CA; Liletta® is a registered trademark of Odyssea Pharma 
SPRL [Belgium], an Allergan affiliate). The methods of the primary study 
have been reported previously (11). Briefly, investigators at 29 sites in the 
United States enrolled healthy nulliparous and parous women aged 16-45 
years (inclusive) who desired a hormonal intrauterine system (IUS) for 
contraception from December 2009 to April 2013. Entry criteria included 


























variation of no more than five days and no abnormality of the uterus 
resulting in distortion of the cavity incompatible with insertion. A local or 
central Institutional Review Board approved the study for each site. Each 
woman signed written informed consent before study participation.
At screening, investigators asked participants to describe their 
baseline and worst menstrual bleeding patterns for the prior 3 months as 
light, normal or heavy flow. We defined self-reported HMB as a response of 
heavy flow for both questions.  Follow-up during the first year included visits 
at one, three, six and 12 months, and a telephone contact at month nine. 
Participants completed a daily paper diary to indicate the greatest amount of
bleeding that day as none, spotting, light flow, normal flow, or heavy flow 
based on their subjective impression. Details of diary instructions and 
completion have been previously published (12). We only included qualifying
cycles for bleeding-related calculations, defined as 23 or more days of 
reporting, and did not impute any missing data.
All analyses only included women who had successful IUS insertion, 
were not using any intrauterine contraception in the month prior to insertion,
attended at least one follow-up visit, and had at least one qualifying cycle of 
diary data. We compared demographic characteristics, bleeding patterns 
and discontinuation rates among women with and without self-reported HMB
at baseline. We evaluated bleeding patterns and discontinuation rates in 28-
day intervals (“cycles”) and defined amenorrhea as no bleeding or spotting 


























We used SAS® 9.3 (Cary, NC) with a p-value of .05 considered statistically 
significant.
Results
Of the 1714 women who enrolled and had successful placement, 1691 
women completed at least one 28-day cycle of follow-up. We excluded 178 
women who had been using intrauterine contraception in the month prior to 
enrollment. Of the 1513 women in the analysis population, 150 (9.9%) self-
reported HMB during the 3 months prior to enrollment. We present 
participant characteristics in Table 1; of note, women with baseline HMB 
were more likely to be African-American.
Changes in bleeding patterns are presented in Figure 1.  By the 28th 
day of levonorgestrel 52mg IUS use, 112 (74.7%, 95% CI 67.7-81.6%) women
reported the absence of subjectively heavy bleeding. By the end of cycle 2, 
124 (83.8%, 95% CI 77.8-89.7%) of the 148 women that started the cycle 
reported no HMB. At the end of cycles 6, 13 and 26, 129/140 (92.1%, 95% CI 
87.7-96.6%), 114/123 (92.7%, 95% CI 88.1-97.3%) and 100/103 (97.1%, 95%
CI 93.8-100%) women reported no HMB, respectively. After cycles 13 and 26,
63/123 (51.2%, 95% CI 42.4-60.1%) and 66/103 (64.1%, 95% CI 54.8-73.3%),
respectively, reported their bleeding as amenorrhea or spotting only. 
Amenorrhea rates are reported in Table 2. Of note, women who self-report 

























of the levonorgestrel 52mg IUS user population, but only during the first 13 
cycles of IUS use.
Women with baseline HMB did not discontinue IUS use more or less 
frequently than those women who did not report subjective baseline HMB 
(Table 3). Only 4 (2.7%) women with baseline HMB discontinued for bleeding 
complaints (2 for HMB and 2 for irregular bleeding), all within the first year. 
These rates did not differ from the discontinuation rates for bleeding 
complaints in the remainder of the study population (Table 3). The reasons 
for discontinuation did not differ between women with and without subjective
baseline HMB (Table 4).
Comment
Principal Findings
We found that women with self-reported HMB have a very rapid and 
dramatic decrease in flow following levonorgestrel 52mg IUS insertion. 
Three-fourths of women report no HMB after just one cycle. During the first 
year of use, women with self-reported HMB report significantly lower 
amenorrhea rates compared to women not reporting HMB. Amenorrhea rates
in the 6th and 13th cycle of levonorgestrel 52 mg IUS use are 60-70% higher 
in women without subjective HMB (Table 2). 
Results
These findings represent women’s subjective views of their bleeding 


























treatment for HMB for regulatory approval. These HMB treatment studies 
require blood loss quantification to ensure a baseline MBL ≥80 mL per cycle. 
Although the studies for regulatory approval measure changes in blood loss, 
they do not describe how quickly blood flow decreases in each of the first 
few months, as was shown in our current study. The two available 
levonorgestrel 52mg IUS products are approved in various countries 
throughout the world as a treatment for HMB based on such studies (4,7). A 
multicenter, single-blind randomized trial in Eastern Europe compared the 
two available levonorgestrel 52mg IUS products in patients with HMB 
utilizing a pictorial blood loss chart to assess MBL and demonstrated equal 
decreases in MBL and increases in ferritin and hemoglobin (4), resulting in 
European Medicines Agency approval of Levosert® (Liletta) in Europe. In the 
U.S., only Mirena® (Bayer Healthcare, Whippany, NJ) is currently approved 
for HMB treatment in women desiring an IUS for contraception. In the trial for
Food and Drug Administration approval, 642 of 807 (79.6%) women failed 
screening, typically because of blood loss that did not meet the 80 mL per 
cycle criterion (7). Thus, it is possible that most women with self-reported 
HMB do not have the degree of MBL evaluated in studies for regulatory 
approval. Although many women who self-report HMB in the general 
population may not have MBL ≥80 mL per cycle, these women still recognize
subjectively significant bleeding reduction. 
Whereas first-line treatment for HMB includes the levonorgestrel 52mg 


























not demonstrated efficacy for HMB treatment. When flow patterns are 
evaluated in young women using a levonorgestrel IUS, more women using 
lower dose products experience prolonged or heavy flow as compared to a 
52mg product (15).
Clinical Implications
This information is important for counseling women with self-reported 
HMB about the expected outcome when using the levonorgestrel 52mg IUS 
for therapeutic purposes to decrease subjectively heavy menstrual flow. 
Although much has been published about the decrease in menstrual flow in 
women using a levonorgestrel 52mg IUS for HMB (16), little is known about 
the effects in women with HMB using the product primarily for contraception.
Because HMB significantly increases with age (17), women who use a LNG 
IUS primarily for HMB likely differ in age and other characteristics from those 
who use it primarily for contraception. Studies evaluating HMB treatment 
with the levonorgestrel 52mg IUS for agency approval in the United States 
and Europe had an average age of 38 years (4,7) whereas women in the 
ACCESS IUS contraceptive trial with self-reported HMB had an average age of
27.5 years.
Strengths and Limitations
A strength of this study is the findings in a diverse population of 
women and daily collection of flow in a diary. Even with this diversity, we are
not powered to adequately evaluate potential racial differences in 


























concerns among women with self-reported baseline HMB. A weakness is that 
the outcomes represent the strictest definitions of bleeding; for example, 
one day of spotting would count as non-amenorrheic. Accordingly, to 
understand the true decrease in bleeding, the rates of amenorrhea or 
spotting rather than amenorrhea alone provide more realistic information for
counseling patients. At one year and beyond, approximately 50%-60% of 
women will report amenorrhea or spotting, with about two-thirds of this 
pattern as spotting.
Research Implications
The number of women in racial subgroups when evaluating 
amenorrhea and discontinuation due to bleeding complaints is too low to 
discriminate these outcomes, especially the rare outcome of discontinuation 
for a bleeding complaint in women with self-reported HMB. Very large 
population-based studies could address these issues.
Conclusions
These findings demonstrate the expected outcomes within young 
women with self-reported heavy bleeding using the levonorgestrel 52mg IUS 
for contraception. A potential benefit of levonorgestrel 52mg IUS use by 
women choosing this method for contraception is the significant decrease in 
flow. Clinicians can use the information provided in this report to better 
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Table 1. Demographics at enrollment for women with and without pre-study 










Age (years) 27.5 + 5.8 26.8 ± 5.5 .17
 ≥36 13 (8.7%) 96 (7.0%) .50
Ethnicity
 Hispanic or Latina 26 (17.3%) 186 (13.6%)
.22
Race .007
 White 99 (66.0%) 1079 (79.2%)
 Black or African American 36 (24.0%) 168 (12.3%)
 Asian 8 (5.3%) 55 (4.0%)
 Multiracial 4 (2.7%) 36 (2.6%)
 American Indian or Alaska Native 3 (2.0%) 16 (1.2%)
 Native Hawaiian or Other Pacific 
Islander
0 5 (0.4%)
 Data missing 0 4 (0.3%)
Body Mass Index (kg/m2) 28.6 + 7.2 26.7 + 6.6 .001
 Obese (≥30.0) 47 (31.3%) 328 (24.1%) .06
Parity
 Nulliparous 84 (56.0%) 839 (61.6%) .19
Marital Status .58
 Never married 93 (62.0%) 896 (65.7%)
 Married 41 (27.3%) 358 (26.3%)
 Divorced 14 (9.3%) 85 (6.2%)
 Separated 2 (1.3%) 22 (1.6%)
 Widowed 0 2 (0.1%)









Data are presented as n (%) or mean ± standard deviation




Table 2.  Amenorrhea rates over 2 years (26 cycles) of levonorgestrel 52mg IUS use among women with 
and without self-reported baseline HMB* (N=1513)
Cycles
of use
Women with baseline HMB
n=150











6 140 21 (15.0%, 9.1-20.9%) 1251 319 (25.5%, 23.1-
27.9%)
.005
13 123 26 (21.1%, 13.9-
28.4%)
1112 382 (34.4%, 31.6-
37.1%)
.003
19 116 36 (31.0%, 22.6-
39.5%)
987 367 (37.2%, 34.2-
40.2%)
.22
26 103 38 (36.9%, 27.6-
46.2%)
880 383 (43.5%, 40.2-
46.8%)
.21
Data are presented as n (%, 95% confidence interval).
HMB=heavy menstrual bleeding; IUS = intrauterine system
* based on self-report of menstrual bleeding patterns for the 3 months prior to screening











Table 3.  Cumulative discontinuation rates over 2 years (26 cycles) of levonorgestrel 52mg IUS use among 


















3 5 (3.3%, 0.5-6.2%) 50 (3.7%, 2.7-4.7%) 1.0 0 2 (0.1%, 0.0-0.3%) 1.0
6 9 (6.0%, 2.2-9.8%) 108 (7.9%, 6.5-9.4%) .52 0 6 (0.4%, 0.1-0.8%) 1.0




.89 1 (0.7%, 0.0-2.0%) 8 (0.6%, 0.2-1.0%) .61




.91 3 (2.0%, 0.0-4.2%) 13 (1.0%, 0.4-1.5%) .21




.17 4 (2.7%, 0.1-5.2%) 22 (1.6%, 0.9-2.3%) .32




.20 4 (2.7%, 0.1-5.2%) 26 (1.9%, 1.2-2.6%) .53
Data are presented as n (%, 95% confidence interval).
HMB=heavy menstrual bleeding; IUS = intrauterine system
* based on self-report of menstrual bleeding patterns for the 3 months prior to screening 











Table 4.  Reasons for discontinuation over 2 years (26 cycles) of levonorgestrel 52mg IUS use among 
women with and without self-reported baseline HMB* (N=1513)






Adverse event (not including 
expulsion or bleeding 
complaint)
12 (5.3%) 136 (8.1%) .56
Lost to follow-up/withdrew 
consent
8 (5.3%) 126 (9.2%) .13
Expulsion 7 (4.7%) 39 (2.9%) .21
Desires pregnancy 5 (3.3%) 43 (3.2%) .81
Bleeding complaint 4 (2.7%) 26 (1.9%) .53
Subject relocation 3 (2.0%) 28 (2.8%) 1.0
Other 3 (2.0%) 56 (4.1%) .27
Data are presented as n (%).
HMB=heavy menstrual bleeding; IUS = intrauterine system
* based on self-report of menstrual bleeding patterns for the 3 months prior to screening 













Flow patterns after levonorgestrel 52mg IUS insertion in women with self-
reported baseline HMB*
Footer:
* Number of women with HMB at baseline is 150; proportion for each cycle is 
calculated based on the number of women using the levonorgestrel 52mg 
IUS during that cycle.
HMB=heavy menstrual bleeding; IUS=intrauterine system 
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